Table 3

Patient groups	ZPT (µm) mean±SD	ZP thin (≤12µm) n (%)	ZP thick (≥17 µm) n (%)
Figure 3. Embryo transfer strategy for each group of POSEIDON patients.
POSEIDON I n=50 <35Y, ≥1.2 ng/ml AMH	15.5±2.2	10 (21%)^b	14 (28%)^a
POSEIDON II n=40 ≥35Y, ≥1.2 ng/ml AMH	15.7±2.0	12 (30%)^a	6 (14%)^c
POSEIDON III n=63 <35Y, <1.2 ng/ml AMH	15.4±1.9	10 (17%)^c	19 (30%)^a
POSEIDON IV n=89 ≥35Y, <1.2 ng/ml AMH	14.1±1.9	30 (34%)^a	9 (10%)^c
Non-POSEIDON <35Y, n=39	15.6±2.1	7 (18%)^c	13 (33%)^a
Non-POSEIDON ≥35Y, n=49	14.7±2.0	14 (27%)^a	8 (17 %)^c
Total n=330	14.9±2.0	81 (25%)	69 (21%)

^a:b, ^b:c values with different superscripts within the same column differ significantly (p<0.05)
^a:c values with different superscripts within the same column differ highly significantly (p<0.001).